Format

Send to

Choose Destination
Expert Opin Biol Ther. 2016 Jul;16(7):859-71. doi: 10.1517/14712598.2016.1170804. Epub 2016 Apr 12.

Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases.

Author information

1
a Multidisciplinary Intensive Care Unit, Department of Anesthesiology and Critical Care , La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, University Pierre and Marie Curie (UPMC) Univ Paris 06 , Paris , France.
2
b Department of Pulmonary Disease , Huadong Hospital, Fudan University , Shanghai , China.
3
c Department of Anesthesiology , University of California San Francisco , San Francisco , CA , USA.

Abstract

INTRODUCTION:

Acute respiratory distress syndrome is a major cause of respiratory failure in critically ill patients. Despite extensive research into its pathophysiology, mortality remains high. No effective pharmacotherapy exists. Based largely on numerous preclinical studies, administration of mesenchymal stem or stromal cell (MSC) as a therapeutic for acute lung injury holds great promise, and clinical trials are currently underway. However, concern for the use of stem cells, specifically the risk of iatrogenic tumor formation, remains unresolved. Accumulating evidence now suggest that novel cell-free therapies including MSC-derived conditioned medium and extracellular vesicles released from MSCs might constitute compelling alternatives.

AREAS COVERED:

The current review summarizes the preclinical studies testing MSC conditioned medium and/or MSC extracellular vesicles as treatment for acute lung injury and other inflammatory lung diseases.

EXPERT OPINION:

While certain logistical obstacles limit the clinical applications of MSC conditioned medium such as the volume required for treatment, the therapeutic application of MSC extracellular vesicles remains promising, primarily due to ability of extracellular vesicles to maintain the functional phenotype of the parent cell. However, utilization of MSC extracellular vesicles will require large-scale production and standardization concerning identification, characterization and quantification.

KEYWORDS:

Acute lung injury; acute respiratory distress syndrome; exosomes; extracellular vesicles; mesenchymal stem cells; microvesicles

PMID:
27011289
PMCID:
PMC5280876
DOI:
10.1517/14712598.2016.1170804
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Declaration of interest This paper was funded by National Institutes of Health grant HL-113022. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center